Conclusions Although within this review the safety of high-dose ivermectin appears to be comparable to standard doses, there are not enough data to support a recommendation for its use in higher-than-approved doses. Ocular adverse events, despite being transient, are of concern in onchocerciasis patients. These data can inform programme managers and guide operational research activities as new approaches for the use of ivermectin are evaluated.
46 posted on 01/04/2022 9:17:52 PM PST by \/\/ayne
(I regret that I have but one subscription cancellation notice to give to my local newspaper)